TapImmune, Inc. announced they will be featured in upcoming Daily Newsletters, Daily Blogs, and Message Boards. QualityStocks has over 750,000 subscribers to The Daily Stock Newsletter, which is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters and puts it all into one Free Daily Newsletter Report.

TapImmune, Inc. is focused on developing innovative therapeutics and vaccines in the areas of oncology and infectious disease. The company’s lead product, the TAP vaccine, moves characteristic markers called antigens to the surfaces of cells. Without TAP, there is a large reduction in presentation of cancer markers, making it difficult for the immune system to spot rogue and cancerous cells, allowing them to grow undetected.

The company’s vaccine has demonstrated its effectiveness in restoring TAP which in-turn restores and augments the characteristic marker (antigen) and subsequent recognition and killing of

...

TapImmune, Inc. is a biotechnology company focused on developing innovative therapeutics and vaccines in the areas of oncology and infectious disease. The company’s lead product, the TAP vaccine, moves characteristic markers called antigens to the surfaces of cells. Without TAP, there are no cancer markers, making it impossible for the immune system to spot rogue cells and cancerous cells, allowing them to grow undetected.

The company’s vaccine has demonstrated its effectiveness in restoring TAP which in-turn restores and augments the characteristic marker (antigen) and subsequent recognition and killing of cancer cells by the immune system. The TAP molecule also works as an accelerant to enhance targeted vaccines against infectious diseases. For example, including TAP in the studied Smallpox Vaccine showed potency was increased by 100-1,000 times.

TapImmune’s technologies have broad applications in developing therapeutic and preventative vaccines. The company’s technologies have been featured on ABC News BusinessNow, B-TV, in BusinessWeek, Popular

...

TapImmune Inc. is a biotechnology company headquartered in Bellevue, Washington. They specialize in the development of immunotherapeutic vaccines for cancer and infectious diseases. Their core business focus is on emerging technologies based on cellular immunology and genetic understanding of the cause and potential novel treatments of disease.

TapImmune Inc.’s lead product is the TAP vaccine. It performs a key step in moving characteristic markers called antigens to the surfaces of cells. Without TAP, there are no cancer markers. Therefore, the immune system fails to spot the rogue cells and the cancerous cells can grow undetected. In addition, the TAP molecule works as an adjuvant (accelerant) to enhance targeted vaccines against infectious diseases.

The Company is developing AdhTAP for the commencement of toxicology studies leading to the initiation of Phase I clinical trials. The expectation is that the global vaccine market will grow from $13 billion in 2007 to $21 billion

...

Becton, Dickinson and Co. (BDX) reported strong fourth quarter and full fiscal 2009 results. For the fourth quarter, earnings per share were $1.25, beating the Zacks Consensus Estimate by a cent and the year-ago earnings by 14 cents. For fiscal 2009, earnings per share came in at $4.95, which was below the Zacks Consensus Estimate by a cent but surpassed the year-ago earnings by 53 cents.  Quarterly Results  Revenues for the reported quarter came in at $1.9 billion as against $1.81 billion in the year-ago quarter, representing an increase of 4.7%. However, revenues grew 8%. excluding the unfavorable impact from foreign currency translation.  In terms of business segments, worldwide BD Medical revenues increased 8.2% to $1.01 billion in the quarter. The growth was driven by strong sales of Pharmaceutical Systems products, coupled with solid sales of Medical Surgical Systems products. Excluding the unfavorable impact from ...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

DrStockPick.com Watch List!

My Picks for Monday October 26, 2009, are:

**************************************************************

BCRX, BioCryst Pharmaceuticals, Inc.

U.S. President Barack Obama has declared 2009 H1N1 swine flu a national emergency, the White House said on Saturday.

BCRX designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer and inflammatory diseases. BCRX has progressed two novel compounds into late-stage pivotal clinical trials; peramivir, an anti-viral for influenza, and forodesine, a purine nucleoside phosphorylase (PNP) inhibitor for cutaneous T-cell lymphoma

The U.S. Food and Drug Administration (FDA), in response to a request from the U.S. Centers for Disease Control and Prevention,

...

Recently, the European Union (EU) approved the proposed $41.1 billion merger between Schering-Plough (SGP) and Merck & Co. (MRK). The deal is awaiting approval from the U.S. Federal Trade Commission. The transaction is expected to close in the fourth quarter of this year. While approving the merger, the EU clarified that the tie-up will not hinder effective competition significantly in Europe, even though both participants in the merger operate in the field of prescription pharmaceuticals. While checking for overlaps in Europe, particularly in the fields of asthma and allergic rhinitis, the European body did not find the products to be close competitors. Consequently, the merger would not be considered to hog the market and choke other companies. As a reminder, Merck filed for EU approval last month after the completion of the sale of its 50% interest in animal health company Merial Limited (Merial) to ...

TOMI Environmental Solutions, Inc. announced this morning that it has delivered a complete set of air remediation equipment for the treatment of infectious disease control to its alliance partner, ROLYN Companies. With plans to use this equipment for their clients in the Maryland, Virginia and Washington D.C. area, ROLYN has already put the TOMI air remediation package to work.

Mark Futrovsky, President of ROLYN, stated, “In conjunction with the TOMI training, we have successfully utilized the TOMI air remediation equipment, and our clients and their consultants have been pleased with the results. The multiple applications of these products and their cost effectiveness have expanded our ability to better serve our client base in need of air remediation and infection disease control services.”

Halden Shane, CEO of TOMI, commented, “The industrial hygienists we encounter on each job continue to be amazed at the effectiveness of our indoor air remediation results, whether

...

Today, Novartis (NVS) acquired exclusive worldwide rights to PTK 0796, a broad spectrum antibiotic from a privately held company, Paratek Pharmaceuticals. The drug is meant for the treatment of infections caused by drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumoniae (MDRSP). PTK 0796, being a broad spectrum antibiotic, could be used as a single agent against a range of bacteria unlike other antibiotics, which may have to be used in combination. Although we are yet to know the exact financial terms of the deal, Novartis will be making an upfront payment to Paratek in addition to future milestone payments and royalties. Both the companies will share the costs and responsibilities related to the drug’s development. A phase III trial for the drug is being conducted for the treatment of complicated skin and skin structure infections (cSSSI). Clinical studies conducted on more ...

Yesterday, Merck & Co. (MRK) announced that it is seeking approval from the European Union (EU) for its $41.1 billion acquisition of Schering-Plough Corp. (SGP). The regulatory authorities in the EU are expected to pass a verdict on the matter by Oct. 23. Merck filed for approval of the merger in the EU after the completion of the sale of its 50% interest in animal health company Merial Limited (Merial) to Sanofi-Aventis (SNY) for a cash consideration of $4 billion ( US ). As a reminder, Merial was founded in 1997. It was a 50/50 joint venture between Merck and Sanofi-Aventis and is now a wholly owned subsidiary of the latter. In 2008, Merial was ranked third in the animal health market, with a market share estimated at 13.8% and sales of $2.7 billion just behind Schering’s animal health business, which registered sales ...

For Immediate Release

Chicago, IL – September 18, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Merck (MRK), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), GlaxoSmithKline (GSK) and Abbott Labs (ABT).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Thursday’s Analyst Blog:

Approval for Merck's Isentress

The European Union (EU) recently expanded the approval of Merck’s (MRK) Isentress (raltegravir) for the first line treatment of HIV patients. Earlier, it was approved for patients who had not responded to other treatment options. In the US, following a recent Food and Drug Administration

...